Showing results (231-240 of 333) with videos related to

Sort By:
Pageof 34
International Journal of Oncology|February 22, 2013
Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinomaHiroaki Kato, Tokuzo Arao, Kazuko Matsumoto, et al.
JAMA Oncology|January 7, 2021
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical TrialHiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation-Positive Non-Small Cell Lung CancerKohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, et al.
Cancer|October 22, 2015
Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomasYasumasa Yoshioka, Yosuke Togashi, Takaaki Chikugo, et al.
Molecular and Clinical Oncology|December 25, 2024
Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer painYoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.
Cancer Management and Research|December 22, 2021
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2021
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancerShinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, et al.
JAMA Oncology|September 7, 2023
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled TrialMotoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.
Future Oncology (London, England)|April 15, 2026
Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design)Tomoki Sakakida, Toshiki Masuishi, Takuma Onoe, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialRoss A Soo, Eng Huat Tan, Hidetoshi Hayashi, et al.
Pageof 34